

Ajay K Gopal

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8628467/ajay-k-gopal-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

185
papers

6,888
citations

38
h-index

80
g-index

192
ext. papers

8,012
ext. citations

4
avg, IF

5.25
L-index

#	Paper	IF	Citations
185	Diagnosis and Management of Multiple Myeloma: A Review.. <i>JAMA - Journal of the American Medical Association</i> , 2022 , 327, 464-477	27.4	32
184	Identification of a genetic signature enriching for response to ibrutinib in relapsed/refractory follicular lymphoma in the DAWN phase 2 trial. <i>Cancer Medicine</i> , 2021 ,	4.8	1
183	Allogeneic Transplant and CAR-T Therapy After Autologous Transplant Failure in DLBCL: A Noncomparative Cohort Analysis. <i>Blood Advances</i> , 2021 ,	7.8	4
182	Umbralisib: Walking the Tightrope of PI3K Inhibition in Indolent NHL. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1671-1673	2.2	
181	Y-labeled anti-CD45 antibody allogeneic hematopoietic cell transplantation for high-risk multiple myeloma. <i>Bone Marrow Transplantation</i> , 2021 , 56, 202-209	4.4	2
180	Yttrium-90 Anti-CD45 Immunotherapy Followed by Autologous Hematopoietic Cell Transplantation for Relapsed or Refractory Lymphoma. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 57.e1-57.e8		5
179	Ibrutinib Monotherapy in Relapsed or Refractory, Transformed Diffuse Large B-cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021 , 21, 176-181	2	4
178	Polatuzumab Vedotin for Relapsed/Refractory Aggressive B-cell Lymphoma: A Multicenter Post-marketing Analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021 , 21, 170-175	2	5
177	Prolonged Lenalidomide Therapy Does Not Impact Autologous Peripheral Blood Stem Cell Mobilization and Collection in Multiple Myeloma Patients: A Single-Center Retrospective Analysis. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 661.e1-661.e6		1
176	Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study. <i>Lancet Haematology,the</i> , 2021 , 8, e562-e571	14.6	4
175	A Phase I trial of talazoparib in patients with advanced hematologic malignancies. <i>International Journal of Hematologic Oncology</i> , 2021 , 10, IJH35	1	
174	Addressing the conundrum of male predominance in mantle cell lymphoma using androgen receptor blockade. <i>British Journal of Haematology</i> , 2020 , 190, e332-e335	4.5	1
173	Biokinetics of Radiolabeled Monoclonal Antibody BC8: Differences in Biodistribution and Dosimetry Among Hematologic Malignancies. <i>Journal of Nuclear Medicine</i> , 2020 , 61, 1300-1306	8.9	3
172	Pembrolizumab with R-CHOP in previously untreated diffuse large B-cell lymphoma: potential for biomarker driven therapy. <i>British Journal of Haematology</i> , 2020 , 189, 1119-1126	4.5	35
171	First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20 Non-Hodgkin Lymphomas. <i>Clinical Cancer Research</i> , 2020 , 26, 2524-2534	12.9	20
170	A phase II trial evaluating the efficacy of high-dose Radioiodinated Tositumomab (Anti-CD20) antibody, etoposide and cyclophosphamide followed by autologous transplantation, for high-risk relapsed or refractory non-hodgkin lymphoma. <i>American Journal of Hematology</i> , 2020 , 95, 775-783	7.1	2
169	Predictors of Cytopenia after Treatment with Axicabtagene Ciloleucel in Patients with Large Cell Lymphoma. <i>Blood</i> , 2020 , 136, 1-2	2.2	1

168	Yttrium-90-labeled anti-CD45 antibody followed by a reduced-intensity hematopoietic cell transplantation for patients with relapsed/refractory leukemia or myelodysplasia. <i>Haematologica</i> , 2020 , 105, 1731-1737	6.6	8
167	KRD-PACE Mobilization for Multiple Myeloma Patients With Significant Residual Disease Before Autologous Stem-Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020 , 20, 602-609	2	2
166	Axicabtagene ciloleucel for relapsed or refractory lymphoma after prior treatment with a different CD19-directed CAR T-cell therapy. <i>Blood Advances</i> , 2020 , 4, 4869-4872	7.8	8
165	Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3095-3106	2.2	78
164	Phosphatidylinositol-3-Kinase Inhibition in Follicular Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2020 , 34, 727-741	3.1	0
163	Selinexor for relapsed or refractory diffuse large B-cell lymphoma: examining the artifact. <i>Lancet Haematology</i> , 2020 , 7, e707	14.6	2
162	Therapy of Myeloid Leukemia using Novel Bispecific Fusion Proteins Targeting CD45 and Y-DOTA. <i>Molecular Cancer Therapeutics</i> , 2020 , 19, 2575-2584	6.1	4
161	Impact of Double- or Triple-Hit Pathology on Rates and Durability of Radiation Therapy Response Among Patients With Relapsed or Refractory Large B-Cell Lymphoma. <i>Practical Radiation Oncology</i> , 2020 , 10, 44-52	2.8	4
160	Phase I Study of a CD45-Targeted Antibody-Radionuclide Conjugate for High-Risk Lymphoma. <i>Clinical Cancer Research</i> , 2019 , 25, 6932-6938	12.9	12
159	Eligibility for CAR T-cell therapy: An analysis of selection criteria and survival outcomes in chemorefractory DLBCL. <i>American Journal of Hematology</i> , 2019 , 94, E117-E116	7.1	9
158	Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy. <i>American Journal of Hematology</i> , 2019 , 94, E209-E213	7.1	39
157	Outcomes of Patients With Therapy-Related MDS After Chemoimmunotherapy for Chronic Lymphocytic Leukemia Compared With Patients With De Novo MDS: A Single-Institution Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019 , 19, 390-395	2	2
156	Phase 2 Study of Daratumumab in Relapsed/Refractory Mantle-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019 , 19, 275-284	2.4	12
155	Where does transplant fit in the age of targeted therapies?. <i>Hematology American Society of Hematology Education Program</i> , 2019 , 2019, 287-293	3.1	2
154	The α -emitter astatine-211 targeted to CD38 can eradicate multiple myeloma in a disseminated disease model. <i>Blood</i> , 2019 , 134, 1247-1256	2.2	16
153	PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL. <i>Blood Advances</i> , 2019 , 3, 360-369	7.8	59
152	Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy. <i>Blood Advances</i> , 2019 , 3, 3062-3069	7.8	37
151	A pilot study of weekly brentuximab vedotin in patients with CD30+ malignancies resistant to brentuximab vedotin every 3 weeks. <i>British Journal of Haematology</i> , 2019 , 186, 159-162	4.5	3

150	Modified VR-CAP, Alternating With Rituximab and High-dose Cytarabine: An Effective Pre-transplant Induction Regimen for Mantle Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019 , 19, 48-52	2	
149	Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2019 , 25, 1718-1726	12.9	20
148	Transplant-Associated Thrombotic Microangiopathy Is a Multifactorial Disease Unresponsive to Immunosuppressant Withdrawal. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 570-576	4.7	27
147	Circulating Plasma Cells at the Time of Collection of Autologous PBSC for Transplant in Multiple Myeloma Patients is a Negative Prognostic Factor Even in the Age of Post-Transplant Maintenance Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 1386-1391	4.7	9
146	Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer. <i>Clinical Cancer Research</i> , 2018 , 24, 1816-1823	12.9	106
145	Total Body Irradiation Is Safe and Similarly Effective as Chemotherapy-Only Conditioning in Autologous Stem Cell Transplantation for Mantle Cell Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 282-287	4.7	7
144	Long-Term Follow-Up of Y-Ibritumomab Tiuxetan, Fludarabine, and Total Body Irradiation-Based Nonmyeloablative Allogeneic Transplant Conditioning for Persistent High-Risk B Cell Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 2211-2215	4.7	6
143	Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma. <i>Blood</i> , 2018 , 132, 777-781	2.2	75
142	Outcomes of Patients with Large B-Cell Lymphomas and Progressive Disease Following CD19-Specific CAR T-Cell Therapy. <i>Blood</i> , 2018 , 132, 94-94	2.2	10
141	Brentuximab vedotin (BV) plus chemotherapy in patients with newly diagnosed advanced stage Hodgkin lymphoma (HL): North American results.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 7541-7541	2.2	4
140	Prolonged Lenalidomide Therapy in Multiple Myeloma Patients Does Not Impact Autologous PBSC Mobilization: A Single Center Retrospective Analysis. <i>Blood</i> , 2018 , 132, 198-198	2.2	
139	CD38-bispecific antibody pretargeted radioimmunotherapy for multiple myeloma and other B-cell malignancies. <i>Blood</i> , 2018 , 131, 611-620	2.2	37
138	Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016. <i>Journal of Clinical Oncology</i> , 2018 , 36, 697-703	2.2	50
137	Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2405-2412	2.2	55
136	Bendamustine, etoposide, and dexamethasone to mobilize peripheral blood hematopoietic stem cells for autologous transplantation in non-Hodgkin lymphoma. <i>Blood Research</i> , 2018 , 53, 223-226	1.4	
135	Bendamustine with rituximab, etoposide and carboplatin (T(R)EC) in relapsed or refractory aggressive lymphoma: a prospective multicentre phase 1/2 clinical trial. <i>British Journal of Haematology</i> , 2018 , 183, 601-607	4.5	6
134	Results of a phase I-II study of fenretinide and rituximab for patients with indolent B-cell lymphoma and mantle cell lymphoma. <i>British Journal of Haematology</i> , 2017 , 176, 583-590	4.5	6
133	Androgen receptor expression in mantle cell lymphoma: Potential novel therapeutic implications. <i>Experimental Hematology</i> , 2017 , 49, 34-38.e2	3.1	8

132	Posterior Reversible Encephalopathy Syndrome Associated With Dose-adjusted EPOCH (Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin) Chemotherapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017 , 17, 225-230	2	12
131	Venetoclax Synergizes with Radiotherapy for Treatment of B-cell Lymphomas. <i>Cancer Research</i> , 2017 , 77, 3885-3893	10.1	18
130	Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy. <i>Blood</i> , 2017 , 129, 3037-3039	2.2	57
129	Recommendations for Clinical Trial Development in Mantle Cell Lymphoma. <i>Journal of the National Cancer Institute</i> , 2017 , 109,	9.7	10
128	Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study. <i>Haematologica</i> , 2017 , 102, e156-e159	6.6	51
127	Spontaneous Remission of an Untreated, MYC and BCL2 Coexpressing, High-Grade B-Cell Lymphoma: A Case Report and Literature Review. <i>Case Reports in Hematology</i> , 2017 , 2017, 2676254	0.7	4
126	Targeted Drugs as Maintenance Therapy after Autologous Stem Cell Transplantation in Patients with Mantle Cell Lymphoma. <i>Pharmaceuticals</i> , 2017 , 10,	5.2	1
125	Pegylated GCSF Can Be Used With First-Line da-EPOCH-R Without Compromising Dose Intensity, Safety, or Efficacy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017 , 17, e87-e90	2	1
124	A Phase I Trial of 90Y-BC8-DOTA (Anti-CD45) Monoclonal Antibody in Combination with Fludarabine and TBI As Conditioning for Allogeneic Peripheral Blood Stem Cell Transplant to Treat High Risk Multiple Myeloma. <i>Blood</i> , 2017 , 130, 910-910	2.2	5
123	Anti-CD45 radioimmunotherapy without TBI before transplantation facilitates persistent haploidentical donor engraftment. <i>Blood</i> , 2016 , 127, 352-9	2.2	24
122	Preserved Activity of CD20-Specific Chimeric Antigen Receptor-Expressing T Cells in the Presence of Rituximab. <i>Cancer Immunology Research</i> , 2016 , 4, 509-19	12.5	16
121	Response assessment in lymphoma: Concordance between independent central review and local evaluation in a clinical trial setting. <i>Clinical Trials</i> , 2016 , 13, 545-54	2.2	2
120	Idelalisib for the treatment of non-Hodgkin lymphoma. <i>Expert Opinion on Pharmacotherapy</i> , 2016 , 17, 265-74	4	21
119	Pretransplantation Minimal Residual Disease Predicts Survival in Patients with Mantle Cell Lymphoma Undergoing Autologous Stem Cell Transplantation in Complete Remission. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 380-385	4.7	28
118	Safety and Activity of Brentuximab Vedotin (BV) Plus Ifosfamide, Carboplatin, and Etoposide (ICE) for Relapsed/Refractory (Rel/Ref) Classical Hodgkin Lymphoma (cHL): Initial Results of a Phase I/II Trial. <i>Blood</i> , 2016 , 128, 1834-1834	2.2	28
117	Management of transaminase elevations in patients receiving idelalisib.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 7532-7532	2.2	
116	Real World Utilization and Practice Patterns of Dose-Adjusted EPOCH for Aggressive B-Cell Lymphomas 2005-2015: Impact of Growth Factor Choice and Resultant Achieved Dose Level. <i>Blood</i> , 2016 , 128, 3577-3577	2.2	
115	Frequency of Amyloid Subtyping Among Patients with Immunoglobulin Light-Chain Amyloidosis Referred for High-Dose Chemotherapy and Autologous Stem Cell Transplant. <i>Blood</i> , 2016 , 128, 5601-5601 ²		

114	Management of Anticoagulation in Patients with Hematologic Malignancy Undergoing Autologous Hematopoietic Cell Transplantation. <i>Blood</i> , 2016 , 128, 1437-1437	2.2	
113	Preclinical safety, pharmacokinetics, pharmacodynamics, and biodistribution studies with Ad35K++ protein: a novel rituximab cotherapeutic. <i>Molecular Therapy - Methods and Clinical Development</i> , 2016 , 5, 16013	6.4	9
112	Pre-transplantation novel agent induction predicts progression-free survival for patients with immunoglobulin light-chain amyloidosis undergoing high-dose melphalan and autologous stem cell transplantation. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2016 , 23, 254-259	2.7	4
111	Comparative Analysis of Bispecific Antibody and Streptavidin-Targeted Radioimmunotherapy for B-cell Cancers. <i>Cancer Research</i> , 2016 , 76, 6669-6679	10.1	21
110	Comorbidities, Alcohol Use Disorder, and Age Predict Outcomes after Autologous Hematopoietic Cell Transplantation for Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 1582-1587	4.7	12
109	Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. <i>Blood</i> , 2016 , 128, 1562-6	2.2	238
108	Radioimmunotherapy and Hematopoietic Cell Transplantation 2016 , 258-275		
107	Autologous transplant for relapsed follicular lymphoma: impact of pre-transplant rituximab sensitivity. <i>Leukemia and Lymphoma</i> , 2015 , 56, 92-6	1.9	5
106	A phase II, single-arm, open-label, multicenter study to evaluate the efficacy and safety of P276-00, a cyclin-dependent kinase inhibitor, in patients with relapsed or refractory mantle cell lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015 , 15, 392-7	2	41
105	Long-term outcomes of patients with persistent indolent B cell malignancies undergoing nonmyeloablative allogeneic transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 281-7	4.7	16
104	Brentuximab vedotin administered to platinum-refractory, transplant-naïve Hodgkin lymphoma patients can increase the proportion achieving FDG PET negative status. <i>Hematological Oncology</i> , 2015 , 33, 187-91	1.3	10
103	Astatine-211 conjugated to an anti-CD20 monoclonal antibody eradicates disseminated B-cell lymphoma in a mouse model. <i>Blood</i> , 2015 , 125, 2111-9	2.2	37
102	High-dose CD20-targeted radioimmunotherapy-based autologous transplantation improves outcomes for persistent mantle cell lymphoma. <i>British Journal of Haematology</i> , 2015 , 171, 788-97	4.5	10
101	Bortezomib and fenretinide induce synergistic cytotoxicity in mantle cell lymphoma through apoptosis, cell-cycle dysregulation, and Bcl-2 kinase downregulation. <i>Anti-Cancer Drugs</i> , 2015 , 26, 974-83	2.4	3
100	Comparative efficacy of 177Lu and 90Y for anti-CD20 pretargeted radioimmunotherapy in murine lymphoma xenograft models. <i>PLoS ONE</i> , 2015 , 10, e0120561	3.7	18
99	Idelalisib Monotherapy and Durable Responses in Patients with Relapsed or Refractory Marginal Zone Lymphoma (MZL). <i>Blood</i> , 2015 , 126, 1543-1543	2.2	10
98	Idelalisib Monotherapy and Durable Responses in Patients with Relapsed or Refractory Small Lymphocytic Lymphoma (SLL). <i>Blood</i> , 2015 , 126, 2743-2743	2.2	2
97	Activity of Idelalisib in High-Risk Follicular Lymphoma with Early Relapse Following Front Line Immunochemotherapy. <i>Blood</i> , 2015 , 126, 2744-2744	2.2	8

96	Analysis of Pre-Transplant Therapy with Brentuximab Vedotin for Relapsed/Refractory Hodgkin Lymphoma on Outcomes of Reduced Intensity Conditioned Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2015 , 126, 4406-4406	2.2	2
95	Idelalisib efficacy and safety in follicular lymphoma patients from a phase 2 study.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 8529-8529	2.2	
94	Idelalisib Treatment Is Associated with Improved Cytopenias in Patients with Relapsed/Refractory iNHL and CLL. <i>Blood</i> , 2015 , 126, 1747-1747	2.2	
93	PI3K inhibition by idelalisib in patients with relapsed indolent lymphoma. <i>New England Journal of Medicine</i> , 2014 , 370, 1008-18	59.2	784
92	R-CHOP with iodine-131 tositumomab consolidation for advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0433. <i>British Journal of Haematology</i> , 2014 , 166, 382-9	4.5	24
91	Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients. <i>Investigational New Drugs</i> , 2014 , 32, 1213-25	4.3	18
90	Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies. <i>Journal of Hematology and Oncology</i> , 2014 , 7, 24	22.4	119
89	Brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30-positive lymphomas: a retrospective evaluation of safety and efficacy. <i>Leukemia and Lymphoma</i> , 2014 , 55, 2328-34 ¹⁹		40
88	Radiolabeled anti-CD45 antibody with reduced-intensity conditioning and allogeneic transplantation for younger patients with advanced acute myeloid leukemia or myelodysplastic syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 1363-8	4.7	47
87	A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia. <i>Blood</i> , 2014 , 123, 1302-8	2.2	59
86	Anti-CD45 radioimmunotherapy with 90Y but not 177Lu is effective treatment in a syngeneic murine leukemia model. <i>PLoS ONE</i> , 2014 , 9, e113601	3.7	13
85	Treatment of relapsed classical Hodgkin lymphoma in the brentuximab vedotin era. <i>Hematology American Society of Hematology Education Program</i> , 2014 , 2014, 151-7	3.1	9
84	90Y-ibritumomab tiuxetan therapy in allogeneic transplantation in B-cell lymphoma with extensive marrow involvement and chronic lymphocytic leukemia: utility of pretransplantation biodistribution. <i>Nuclear Medicine Communications</i> , 2014 , 35, 1132-42	1.6	2
83	A preclinical model of CD38-pretargeted radioimmunotherapy for plasma cell malignancies. <i>Cancer Research</i> , 2014 , 74, 1179-89	10.1	40
82	Myeloablative I-131-tositumomab with escalating doses of fludarabine and autologous hematopoietic transplantation for adults age 16-60 years with B cell lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 770-5	4.7	18
81	Mature Follow up from a Phase 2 Study of PI3K-Delta Inhibitor Idelalisib in Patients with Double (Rituximab and Alkylating agent)-Refractory Indolent B-Cell Non-Hodgkin Lymphoma (iNHL). <i>Blood</i> , 2014 , 124, 1708-1708	2.2	9
80	Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016. <i>Journal of Clinical Oncology</i> , 2013 , 31, 314-20	2.2	138
79	Specific features identify patients with relapsed or refractory mantle cell lymphoma benefitting from autologous hematopoietic cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013 , 19, 1403-6	4.7	22

78	A phase I study of pulse high-dose vorinostat (V) plus rituximab (R), ifosphamide, carboplatin, and etoposide (ICE) in patients with relapsed lymphoma. <i>British Journal of Haematology</i> , 2013 , 161, 183-91	4.5	27
77	A comparative analysis of prognostic factor models for follicular lymphoma based on a phase III trial of CHOP-rituximab versus CHOP + 131iodine--tositumomab. <i>Clinical Cancer Research</i> , 2013 , 19, 6624-32	12.9	31
76	Anti-CD45 radioimmunotherapy using (211)At with bone marrow transplantation prolongs survival in a disseminated murine leukemia model. <i>Blood</i> , 2013 , 121, 3759-67	2.2	51
75	A Phase I Study Of Myeloablative Radioimmunotherapy Using Iodine-131 Anti-CD45 Antibody Followed By Autologous Stem Cell Transplantation For High-Risk B-Cell and T-Cell Non-Hodgkin Lymphoma and Hodgkin Lymphoma. <i>Blood</i> , 2013 , 122, 3333-3333	2.2	1
74	A Phase I/II Study Of Fludarabine, Cyclophosphamide, Rituximab and Vorinostat Followed By Rituximab and Vorinostat Maintenance Therapy In Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia (CLL) Or Small Lymphocytic Leukemia (SLL). <i>Blood</i> , 2013 , 122, 4191-4191	2.2	1
73	Three-Year Follow-Up Data and Characterization Of Long-Term Remissions From An Ongoing Phase 2 Study Of Brentuximab Vedotin In Patients With Relapsed Or Refractory Hodgkin Lymphoma. <i>Blood</i> , 2013 , 122, 4382-4382	2.2	14
72	Mature Response Data From a Phase 2 Study Of PI3K-Delta Inhibitor Idelalisib In Patients With Double (Rituximab and Alkylating Agent)-Refractory Indolent B-Cell Non-Hodgkin Lymphoma (iNHL). <i>Blood</i> , 2013 , 122, 85-85	2.2	7
71	131I-Tositumomab Consolidation Radioimmunotherapy (RIT) In Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Or Small Lymphocytic Lymphoma (SLL) In First Remission. <i>Blood</i> , 2013 , 122, 1644-1644	2.2	
70	Astatine-211 Conjugated To Anti-CD20 Monoclonal Antibody Eliminates B-Cell Lymphoma In a Mouse Model. <i>Blood</i> , 2013 , 122, 4415-4415	2.2	
69	Impact Of Pre-Transplant Rituximab Sensitivity In Relapsed Follicular Lymphoma On Outcome After Autologous Transplant. <i>Blood</i> , 2013 , 122, 3365-3365	2.2	
68	Bendamustine (Treanda [®]) -Based Regimens Are Effective In Mobilizing Peripheral Blood Hematopoietic Stem Cells For Autologous Transplantation. <i>Blood</i> , 2013 , 122, 2033-2033	2.2	
67	Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin ^B lymphoma. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2183-9	2.2	1091
66	Allogeneic hematopoietic cell transplantation in mantle cell lymphoma. <i>Best Practice and Research in Clinical Haematology</i> , 2012 , 25, 165-74	4.2	4
65	Treatment strategies for Hodgkin lymphoma recurring following autologous hematopoietic stem cell transplantation. <i>The Korean Journal of Hematology</i> , 2012 , 47, 8-16		6
64	The effective use of plerixafor as a real-time rescue strategy for patients poorly mobilizing autologous CD34(+) cells. <i>Journal of Clinical Apheresis</i> , 2012 , 27, 81-7	3.2	22
63	Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation. <i>Blood</i> , 2012 , 120, 560-8	2.2	140
62	131I-tositumomab myeloablative radioimmunotherapy for non-Hodgkin ^B lymphoma: radiation dose to the testes. <i>Nuclear Medicine Communications</i> , 2012 , 33, 1225-31	1.6	2
61	Randomized Comparison of Melphalan 200 Mg/m ² v. 280 Mg/m ² As a Preparative Regimen for Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation. <i>Blood</i> , 2012 , 120, 2009-2009	2.2	1

60	Retrospective Analysis of the Safety and Efficacy of Brentuximab Vedotin in Patients Aged 60 Years or Older with Relapsed or Refractory CD30+ Hematologic Malignancies. <i>Blood</i> , 2012 , 120, 3687-3687	2.2	2
59	Long-Term Survival Analyses of an Ongoing Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Hodgkin Lymphoma. <i>Blood</i> , 2012 , 120, 3689-3689	2.2	3
58	Overall Survival Benefit for Patients with Relapsed Hodgkin Lymphoma Treated with Brentuximab Vedotin After Autologous Stem Cell Transplant. <i>Blood</i> , 2012 , 120, 3701-3701	2.2	6
57	Bendamustine (Treanda [®]), Etoposide and Dexamethasone (BED) Followed by GCSF Effectively Mobilizes Autologous Peripheral Blood Hematopoietic Stem Cells. <i>Blood</i> , 2012 , 120, 4126-4126	2.2	1
56	Hematopoietic Bone Marrow Transplantation (BMT) for Patients with High-Risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS) Using HLA-Haploidentical Related Donors: A Trial Using Radiolabeled Anti-CD45 Antibody Combined with Immunosuppression Before and After BMT. <i>Blood</i> , 2012 , 120, 4164-4164	2.2	3
55	What is the role of transplantation for indolent lymphoma?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2012 , 494-500	7.1	1
54	A Phase II Trial of Myeloablative I-131-Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Transplantation for B-Cell Non-Hodgkin [®] Lymphoma. <i>Blood</i> , 2012 , 120, 811-811	2.2	
53	Anti-CD45 Radioimmunotherapy Using the Alpha-Emitting Radionuclide 211At Combined with Bone Marrow Transplantation Prolongs Survival in a Disseminated Murine Leukemia Model. <i>Blood</i> , 2012 , 120, 4096-4096	2.2	
52	A Phase II Trial Combining Radiolabeled Anti-CD45 Antibody with Fludarabine and Low-Dose Total Body Irradiation (TBI) Followed by Related or Unrelated Hematopoietic Cell Transplantation for Patients Under Age 50 with Advanced Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS). <i>Blood</i> , 2012 , 120, 1924-1924	2.2	
51	Anti-CD45 Radioimmunotherapy Facilitates Donor Engraftment and Prolongs Survival in the Absence of TBI Prior to Haploidentical Bone Marrow Transplantation in a Disseminated Murine Leukemia Model. <i>Blood</i> , 2012 , 120, 4101-4101	2.2	
50	Phase 1b Study of TRU-016, an Anti-CD37 SMIP [®] Protein, in Combination with Rituximab and Bendamustine in Relapsed Indolent Lymphoma. <i>Blood</i> , 2012 , 120, 3678-3678	2.2	
49	Full Dose Bendamustine (Treanda [®]) Can Be Safely Combined with Rituximab, Etoposide and Carboplatin (TREC): Results of a Phase I Trial in Patients with Relapsed or Refractory Lymphoma. <i>Blood</i> , 2012 , 120, 3650-3650	2.2	
48	Histology and time to progression predict survival for lymphoma recurring after reduced-intensity conditioning and allogeneic hematopoietic cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011 , 17, 1537-45	4.7	28
47	⁹⁰ Y-Ibritumomab tiuxetan, fludarabine, and TBI-based nonmyeloablative allogeneic transplantation conditioning for patients with persistent high-risk B-cell lymphoma. <i>Blood</i> , 2011 , 118, 1132-9	2.2	56
46	Pretargeted radioimmunotherapy using genetically engineered antibody-streptavidin fusion proteins for treatment of non-hodgkin lymphoma. <i>Clinical Cancer Research</i> , 2011 , 17, 7373-82	12.9	24
45	Mantle cell lymphoma international prognostic index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantation. <i>Journal of Clinical Oncology</i> , 2011 , 29, 3023-9	2.2	58
44	Allogeneic Transplant Following Brentuximab Vedotin Treatment in Patients with Relapsed or Refractory CD30+ Lymphomas. <i>Blood</i> , 2011 , 118, 3091-3091	2.2	6
43	Prolonged Treatment with Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL),. <i>Blood</i> , 2011 , 118, 3711-3711	2.2	7

42	Phase 1 Study of TRU-016, An Anti-CD37 SMIP Protein in Relapsed and/or Refractory NHL Patients. <i>Blood</i> , 2011 , 118, 1636-1636	2.2	1
41	A Phase I Study of Myeloablative I-131-Anti CD-20 (Tositumomab) Radioimmunotherapy with Escalating Doses of Fludarabine Followed by Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Adults 16 Years of Age with High-Risk or Relapsed/Refractory B-Cell Lymphoma. <i>Blood</i> , 2011 , 118, 1637-1643	2.2	1
40	Efficacy and safety of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed/refractory lymphoma: a prospective multi-center phase II study by the Puget Sound Oncology Consortium. <i>Leukemia and Lymphoma</i> , 2010 , 51, 1523-9	1.9	41
39	Recent advances in novel radioimmunotherapeutic approaches for allogeneic hematopoietic cell transplantation. <i>Current Opinion in Oncology</i> , 2010 , 22, 143-9	4.2	3
38	Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease. <i>Blood</i> , 2010 , 116, 4231-9	2.2	54
37	Preclinical and Clinical Binding Properties, Internalization Kinetics, and Clinicopathological Activity of Brentuximab Vedotin (SGN-35): A Novel Antibody Drug Conjugate for Anaplastic Large Cell Lymphoma and Classical Hodgkin Lymphoma. <i>Blood</i> , 2010 , 116, 1789-1789	2.2	5
36	Radioimmunoconjugates in hematopoietic stem cell transplantation. <i>Cancer Treatment and Research</i> , 2009 , 144, 299-315	3.5	1
35	Pretargeted radioimmunotherapy using anti-CD45 monoclonal antibodies to deliver radiation to murine hematolymphoid tissues and human myeloid leukemia. <i>Cancer Research</i> , 2009 , 69, 185-92	10.1	21
34	Pretargeting CD45 enhances the selective delivery of radiation to hematolymphoid tissues in nonhuman primates. <i>Blood</i> , 2009 , 114, 1226-35	2.2	31
33	Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome. <i>Blood</i> , 2009 , 114, 5444-53	2.2	137
32	A comparative analysis of conventional and pretargeted radioimmunotherapy of B-cell lymphomas by targeting CD20, CD22, and HLA-DR singly and in combinations. <i>Blood</i> , 2009 , 113, 4903-13	2.2	47
31	131I anti-CD45 radioimmunotherapy effectively targets and treats T-cell non-Hodgkin lymphoma. <i>Blood</i> , 2009 , 113, 5905-10	2.2	22
30	Radioimmunotherapy-based conditioning regimens for stem cell transplantation. <i>Seminars in Hematology</i> , 2008 , 45, 118-25	4	33
29	High-dose chemotherapy with BEAM or Busulphan/Melphalan and Thiotepa followed by hematopoietic cell transplantation in malignant lymphoma. <i>Leukemia and Lymphoma</i> , 2008 , 49, 1899-906	1.9	22
28	Effect of remission status and induction chemotherapy regimen on outcome of autologous stem cell transplantation for mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2008 , 49, 1062-73	1.9	35
27	Myeloablative 131I-tositumomab radioimmunotherapy in treating non-Hodgkin B lymphoma: comparison of dosimetry based on whole-body retention and dose to critical organ receiving the highest dose. <i>Journal of Nuclear Medicine</i> , 2008 , 49, 837-44	8.9	15
26	Extracorporeal adsorption therapy: a method to improve targeted radiation delivered by radiometal-labeled monoclonal antibodies. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2008 , 23, 181-93	3.9	4
25	Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. <i>Blood</i> , 2008 , 112, 2261-71	2.2	540

24	Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab. <i>Blood</i> , 2008 , 112, 830-5	2.2	76
23	Eradication of disseminated leukemia in a syngeneic murine leukemia model using pretargeted anti-CD45 radioimmunotherapy. <i>Blood</i> , 2008 , 111, 2261-8	2.2	31
22	High-dose therapy and autologous stem cell transplantation for chemoresistant Hodgkin lymphoma: the Seattle experience. <i>Cancer</i> , 2008 , 113, 1344-50	6.4	33
21	The pretransplant Follicular Lymphoma International Prognostic Index is associated with survival of follicular lymphoma patients undergoing autologous hematopoietic stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2007 , 48, 1961-7	1.9	14
20	Evaluation of CD20, CD22, and HLA-DR targeting for radioimmunotherapy of B-cell lymphomas. <i>Cancer Research</i> , 2007 , 67, 5921-8	10.1	39
19	High-dose [¹³¹ I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults > or = 60 years old with relapsed or refractory B-cell lymphoma. <i>Journal of Clinical Oncology</i> , 2007 , 25, 1396-402	2.2	105
18	Adoptive Cellular Therapy for Follicular Lymphoma Using Genetically-Modified Autologous CD20-Specific T Cells.. <i>Blood</i> , 2007 , 110, 499-499	2.2	0
17	Radioimmunotherapy of Lymphomas 2007 , 147-160		
16	Outcomes after Autologous Stem Cell Transplantation for Mantle Cell Lymphoma Based on Remission Status and Induction Chemotherapy Regimen.. <i>Blood</i> , 2007 , 110, 1905-1905	2.2	
15	Improving the efficacy of reduced intensity allogeneic transplantation for lymphoma using radioimmunotherapy. <i>Biology of Blood and Marrow Transplantation</i> , 2006 , 12, 697-702	4.7	34
14	131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission. <i>Blood</i> , 2006 , 107, 2184-91	2.2	132
13	A Phase II Trial of 90Y-Ibritumomab Tiuxetan-Based Reduced Intensity Allogeneic Peripheral Blood Stem Cell (PBSC) Transplantation for Relapsed CD20+ B-Cell Non-Hodgkins Lymphoma (NHL).. <i>Blood</i> , 2006 , 108, 316-316	2.2	10
12	131I-Anti-CD45 Antibody Plus Fludarabine, Low-Dose Total Body Irradiation and Peripheral Blood Stem Cell Infusion for Elderly Patients with Advanced Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS).. <i>Blood</i> , 2005 , 106, 397-397	2.2	18
11	A Phase II Study of Myeloablative I-131-Anti CD-20 (Tositumomab) Radioimmunotherapy and Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Adults ≥0 Years of Age with High-Risk Relapsed or Refractory B-Cell Lymphoma.. <i>Blood</i> , 2005 , 106, 487-487	2.2	4
10	Comparison of radiation dose estimation for myeloablative radioimmunotherapy for relapsed or recurrent mantle cell lymphoma using (131)I tositumomab to that of other types of non-Hodgkin lymphoma. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2004 , 19, 738-45	3.9	5
9	Fenretinide enhances rituximab-induced cytotoxicity against B-cell lymphoma xenografts through a caspase-dependent mechanism. <i>Blood</i> , 2004 , 103, 3516-20	2.2	29
8	High-dose (131)I-tositumomab (anti-CD20) radioimmunotherapy for non-Hodgkin lymphoma: adjusting radiation absorbed dose to actual organ volumes. <i>Journal of Nuclear Medicine</i> , 2004 , 45, 1059-64	8.9	21
7	High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis. <i>Blood</i> , 2003 , 102, 2351-7	2.2	172

6	High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. <i>Blood</i> , 2002 , 99, 3158-62	2.2	187
5	Prospective analysis of <i>Staphylococcus aureus</i> bacteremia in nonneutropenic adults with malignancy. <i>Journal of Clinical Oncology</i> , 2000 , 18, 1110-5	2.2	56
4	A phase I/II trial of iodine-131Bositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. <i>Blood</i> , 2000 , 96, 2934-2942	2.2	242
3	A phase I/II trial of iodine-131Bositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. <i>Blood</i> , 2000 , 96, 2934-2942	2.2	6
2	Clinical applications of anti-CD20 antibodies. <i>Translational Research</i> , 1999 , 134, 445-50		90
1	Cranial computed tomography before lumbar puncture: a prospective clinical evaluation. <i>Archives of Internal Medicine</i> , 1999 , 159, 2681-5		68